EpiFrontier Therapeutics received $32 million to advance EPF-001 for the treatment of sickle cell disease, a rare blood disorder.
City: Pennington
State: NJ
Investment Amount (In Millions): $32
EpiFrontier Therapeutics received $32 million to advance EPF-001 for the treatment of sickle cell disease, a rare blood disorder.
City: Pennington
State: NJ
Investment Amount (In Millions): $32